NCT03579823View on ClinicalTrials.gov

Comparative Safety, Tolerability, Pharmacokinetic Study of AVT02 (100MG/ML) and Humira (100MG/ML) in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 21, 2018

Primary Completion Date

August 24, 2018

Study Completion Date

August 24, 2018

Conditions
Healthy Volunteers
Interventions
DRUG

Adalimumab 100 MG/ML [Humira]

prefilled syringe at a concentration of 100MG/ML and delivering 40MG of adalimumab, as a single dose on day 1 day 1

DRUG

AVT02 100MG/ML

prefilled syringe at a concentration of 100MG/ML delivering 40MG of AVT02, as a single dose on day 1 day 1

Trial Locations (1)

3004

Nucleus Network, Melbourne

All Listed Sponsors
lead

Alvotech Swiss AG

INDUSTRY

NCT03579823 - Comparative Safety, Tolerability, Pharmacokinetic Study of AVT02 (100MG/ML) and Humira (100MG/ML) in Healthy Volunteers | Biotech Hunter | Biotech Hunter